Our work demonstrate that the persistent signaling by mutated EGFR in TKI‐resistant tumor cells relies on palmitoylation of EGFR and can be targeted by Orlistat, an FDA‐approved anti‐obesity drug. This evidence concerns the gene EGFR and obesity due to melanocortin 4 receptor deficiency.